SHC vs STE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SHC and STE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SHC and STE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to June 30, 2026 was ~$1.22 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Full SHC guide

STERIS plc makes the equipment, chemistries and services that keep hospital operating rooms and medical device production sterile. Three segments carry the business. Healthcare, roughly ~70% of revenue, sells sterilizers, washers, surgical tables, endoscopy reprocessing systems and the consumables and service contracts that follow them into hospitals. Applied Sterilization Technologies (AST), close to ~20% of revenue, runs contract sterilization facilities that gamma-irradiate, e-beam or ethylene oxide treat devices for manufacturers before those devices ship. Life Sciences, near ~10%, supplies cleaning chemistries, small sterilizers and validation services to pharmaceutical producers. Legally the parent is an Irish plc, operationally the company runs out of Mentor, Ohio, and the ordinary shares trade on the NYSE inside the S&P 500. Headcount is roughly ~17,900.

Full STE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• SHC drivers: Contracted volume and repeat pricing; Nordion's cobalt-60 position and the harvest cycle.
• STE drivers: Recurring consumables and service, not equipment sales; Outsourced sterilization volume tied to device manufacturing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The ethylene oxide tort docket is the dominant, partly quantified risk. For STE, ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SHC if you believe its drivers more; STE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SHC and STE guides.

SHC. Roughly 12x enterprise value to adjusted EBITDA is a modest price for a business earning 51% EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation. Sotera carries no reserve for the ~970 ethylene oxide claims still outstanding, so the multiple embeds an unpriced tail rather than a known cost. The trailing GAAP P/E of ~34x, meanwhile, reflects amortization, interest and settlement charges that the adjusted figures strip out.

STE. STERIS runs a March fiscal year, so the trailing twelve months as of August 2026 spans the final three quarters of fiscal 2026 plus the June 2026 quarter that opened fiscal 2027. Fiscal 2027 first quarter revenue rose ~7% to ~$1.5 billion with adjusted EPS of ~$2.59, and full-year guidance of ~7% to ~8% reported growth was reiterated. The gap between the ~29x trailing and ~21x forward multiple reflects both expected earnings growth of ~9% to ~11% and the sizeable adjustments, including amortization and restructuring, that separate GAAP EPS from the adjusted figure guidance is built on.

Headline figures (approximate, August 2026): SHC shows revenue (ttm) ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit., earnings and eps GAAP net income of ~$163.5 million for the twelve months to June 30, 2026, against $77.9 million in fiscal 2025 and $44.3 million in fiscal 2024. Trailing diluted EPS is $0.57, putting the shares near 34x reported earnings. The year-on-year comparison flatters 2026 because fiscal 2025 absorbed $64.9 million of Illinois settlement charges and heavier intangible amortization. Q2 2026 net income was $53.6 million ($0.19 diluted) versus $8.0 million ($0.03) a year earlier; adjusted EPS of $0.26 rose 30%, and full-year adjusted EPS guidance is $0.95 to $1.01., segment mix and margins For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In the second quarter of 2026 those revenues were $211.6 million, $49.1 million and $60.7 million, with segment income of $118.1 million, $28.0 million and $19.6 million. Consolidated adjusted EBITDA margin was 51.6% in the quarter and 51.1% on a trailing twelve-month basis. Nelson Labs is the swing factor, having fallen 3.9% in 2025., cash flow and capital spending Net cash from operating activities was $117.9 million in the first half of 2026 versus $112.9 million a year earlier, with $88 million of it in the second quarter. Capital expenditure was $92.6 million in the half against $51.1 million in the prior-year half, and full-year 2026 guidance is $200 million to $225 million, close to 17% of revenue. Free cash flow is therefore a small fraction of the $621.6 million of trailing adjusted EBITDA, because cobalt supply, plant capacity and emissions controls all consume cash.; STE shows revenue (ttm) ~$6.04 billion, market cap ~$23.2 billion at a share price near ~$239, trailing p/e ~29x on trailing EPS of ~$8.18, forward p/e ~21x on fiscal 2027 adjusted EPS guidance of ~$11.10 to ~$11.30.

SHC and STE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SHC and STE exposure against your real portfolio. It is not an investment adviser.